rs63750447
Variant summary
The NM_000249.4(MLH1):c.1151T>A (p.Val384Asp) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a cumulative frequency of 0.00101 (AC=1,631) in the gnomAD database across 1,613,706 control chromosomes, including 21 homozygotes. The grpmax filtering allele frequency (95% CI) is 0.0332. In-silico predictor (REVEL) classifies this variant as likely damaging/oncogenic. Splicing prediction tools (SpliceAI) predict no significant impact on normal splicing. The affected nucleotide is highly conserved across species (PhyloP 100-way vertebrate score: 7.34). Variant has been reported in ClinVar as Benign/Likely Benign (★★★). Other variants at the same amino acid position have been reported in ClinVar (not pathogenic): p.V384A: Uncertain_significance (ClinVar VariationId 3635648, 1 star); p.V384F: Uncertain_significance (ClinVar VariationId 818423, 2 stars); p.V384I: Conflicting_classifications_of_pathogenicity (ClinVar VariationId 405421); p.V384= (synonymous): Likely_benign (ClinVar VariationId 818432, 2 stars) This exact variant is established as oncogenic in: CGI (Cancer Genome Interpreter). This exact variant is curated in the UniProt human variants database as Uncertain Significance; it is also listed as a COSMIC curated somatic variant.
Frequency
Consequence
NM_000249.4 missense
Scores
Clinical Significance
Conservation
Publications
- Lynch syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, G2P, Orphanet
- Lynch syndrome 2Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, Ambry Genetics
- Muir-Torre syndromeInheritance: AD Classification: DEFINITIVE, STRONG, MODERATE Submitted by: Genomics England PanelApp, G2P, Ambry Genetics
- mismatch repair cancer syndrome 1Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, ClinGen, Labcorp Genetics (formerly Invitae), G2P, Ambry Genetics
- Lynch syndrome 1Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
- ovarian cancerInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
- malignant pancreatic neoplasmInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- rhabdomyosarcomaInheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
- prostate cancerInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
- breast cancerInheritance: AD Classification: NO_KNOWN Submitted by: Ambry Genetics
- hereditary breast carcinomaInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
Classification according to ACMG Germline Pathogenicity v2019
Our verdict: Benign. The variant received -15 points.
| Apply | Criterion Code & Title / Strength | Rationale / Clinical Context | |
|---|---|---|---|
| PP3Computational evidence supports damaging effect | Germline meta computational scorer (REVEL/MetaRNN/BayesDel) predicts damaging effect — supporting evidence (PP3); Splicing verdict: not pathogenic.; Germline computational verdict: pathogenic (Supporting). | ||
| BP6Reputable source reports benign | ClinVar ≥3 stars benign — very strong (BP6); ClinVar submissions overwhelmingly benign (≥10 total, ≥80% B/LB, <10% P/LP) — strong (BP6, count-based); ClinVar germline classification: Benign/Likely Benign, 3 star(s). ClinVar submissions strongly and reliably favor benignity (27/27 total B/LB). | ||
| BS1Allele frequency higher than expected | GnomAD effective popmax AF above BS1 threshold — greater than expected for disorder; GnomAD effective popmax AF = 0.0332 vs gene BS1 threshold 0.015. | ||
| BS2Observed in healthy adult | ≥2 homozygotes in gnomAD — observed in healthy adults (BS2); GnomAD homozygous count = 21.; Very high cumulative gnomAD AC = 1631 (any gene). |
Variant Effect in Transcripts
Automated classification analysis was done for transcript: NM_000249.4. You can select a different transcript below to see updated classification assignments.
RefSeq Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| MLH1 | MANE Select | c.1151T>A | p.Val384Asp | missense | Exon 12 of 19 | NP_000240.1 | P40692-1 | ||
| MLH1 | c.1151T>A | p.Val384Asp | missense | Exon 12 of 18 | NP_001341557.1 | A0A087WX20 | |||
| MLH1 | c.1052T>A | p.Val351Asp | missense | Exon 11 of 18 | NP_001341558.1 | A0AAQ5BGZ2 |
Ensembl Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| MLH1 | TSL:1 MANE Select | c.1151T>A | p.Val384Asp | missense | Exon 12 of 19 | ENSP00000231790.3 | P40692-1 | ||
| MLH1 | TSL:1 | c.1151T>A | p.Val384Asp | missense | Exon 12 of 17 | ENSP00000416687.3 | H0Y818 | ||
| MLH1 | TSL:1 | c.1151T>A | p.Val384Asp | missense | Exon 12 of 15 | ENSP00000416476.2 | H0Y806 |
Frequencies
Allele frequencies (AF), counts (AC/AN), homozygotes and coverage
| Source / population | AF | AC | Hom | AN | Coverage |
|---|---|---|---|---|---|
Global population databases 6 sources | |||||
GnomAD3 genomes | AF: 0.00105 | AC:160 | Hom:2 | AN:151706 | Cov:31 |
GnomAD2 exomes | AF: 0.00271 | AC:682 | AN:251422 | ||
GnomAD4 exome | AF: 0.00101 | AC:1471 | Hom:19 | AN:1461884 | Cov:34 |
GnomAD4 genome | AF: 0.00105 | AC:160 | Hom:2 | AN:151822 | Cov:31 |
TOPMed (Bravo) | AF: 0.00142 | ||||
ALFA (dbGaP/dbSNP Allele Frequency Aggregator) | AF: 0.000224 | AC:6 | Hom:0 | AN:26752 | |
Local & regional cohorts 8 sources | |||||
ChinaMAP Phase 1 | AF: 0.0337 | ||||
ESP6500 (Exome Variant Server) | AF: 0.0000769 | AC:1 | AN:13006 | ||
GenomeAsia100K | AF: 0.00982 | AC:34 | AN:3478 | ||
Korea4K (4,157 Koreans) | AF: 0.0400 | AC:292 | AN:7230 | ||
ToMMo 61KJPN (+60KJPN MNV) | AF: 0.0344 | AC:4208 | Hom:84 | AN:122256 | |
Turkish Variome | AF: 0.00129 | AC:2 | Hom:0 | AN:1546 | |
UK10K | AF: 0.000132 | AC:1 | AN:7562 | ||
WBBC (Westlake BioBank for Chinese) pilot | AF: 0.0300 | AC:269 | Hom:3 | AN:8960 | |
Case/control cohorts
| Cohort | Cases | Controls | ||||
|---|---|---|---|---|---|---|
| AF | AC | AN | AF | AC | AN | |
Epi25 | 0.00276 | 116 | 41958 | 0.00126 | 84 | 66888 |
SCHEMA | 0.0101 | 1241 | 123046 | 0.00685 | 1315 | 191916 |
ClinVar
Computational Scores
| Algorithm | Calibrated pred. | Score | Prediction |
|---|---|---|---|
AlphaGenome AVI | Pathogenic | 34 | |
AlphaMissense | Pathogenic | 1.0 | |
BayesDel_addAF | Uncertain | 0.12 | D |
BayesDel_noAF | Pathogenic | 0.43 | |
CADD | Pathogenic | 27 | |
DANN | Uncertain | 0.99 | |
DEOGEN2 | Pathogenic | 0.86 | D |
Eigen | Pathogenic | 0.90 | |
Eigen_PC | Pathogenic | 0.84 | |
FATHMM_MKL | Pathogenic | 0.97 | D |
FuncVEP CTI | Pathogenic | 0.73 | |
GPN-Star LLR | N/A | -10 | |
GPN-Star score | N/A | 10 | |
LIST_S2 | Uncertain | 0.97 | D |
MetaRNN | Benign | 0.010 | T |
MetaSVM | Uncertain | 0.52 | D |
Mutation Taster | N/A | 88/12 | polymorphism |
MutationAssessor | Uncertain | 2.6 | M |
PhyloP100 | Uncertain | 7.3 | |
popEVE | Benign | -3.4 | |
PrimateAI | Uncertain | 0.58 | T |
PromoterAI | N/A | 0.020 | Neutral |
PROVEAN | Pathogenic | -5.6 | D |
REVEL | Pathogenic | 0.73 | |
Sift | Pathogenic | 0.0 | D |
Sift4G | Pathogenic | 0.0 | D |
Varity_R | N/A | 0.92 | |
VESM-3B | Benign | -15 |
Splicing Scores
| Algorithm | Calibrated pred. | Score | Prediction |
|---|---|---|---|
Pangolin (max) | Benign | 0.0 | |
SpliceAI score (max) | Benign | 0.0 | Details are displayed if max score is > 0.2 |
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.